Abstract
Background Late-gadolinium enhanced (LGE)-MRI has revealed atrial fibrotic remodeling in embolic stroke of undetermined source (ESUS) patients comparable to that observed in atrial fibrillation (AFib) patients. The absence of AFib in ESUS patients may be due to differences in the fibrotic substrate characteristics or the lack of triggers needed to initiate AFib. We used simulations in computational models reconstructed from LGE-MRI scans to study the role of atrial fibrosis as a pathophysiological link between AFib and ESUS.
Methods ESUS (per standard criteria) was verified by a neurologist. 45 ablation-naïve AFib patients and 45 ESUS patients within three months of stroke underwent LGE-MRI for fibrosis assessment. Left atrial (LA) models were built from LGE-MRI scans. Fiber orientations were mapped into each LA model using universal atrial coordinates. Burst pacing from 15 known AFib trigger sites was used to test inducibility of arrhythmia sustained by reentry.
Results We observed sustained reentry in 23/45 (51%) ESUS and 28/45 (62%) AFib models. Overall, the fibrosis burden was significantly higher for patients in whom simulations showed inducibility (16.8 ± 5.04% vs. 10.19 ± 3.14%; P<0.0001); however, within the inducible and non-inducible sub-groups, there was no significant difference in fibrosis burden for ESUS vs. AFib patients (P=0.068 and P=0.58, respectively). This suggests that the presence of a pre-clinical substrate in ESUS is correlated with fibrosis burden, although exceptions to this supposition were not uncommon (i.e., inducible low-fibrosis and non-inducible high-fibrosis models).
Conclusions In this modeling study, pro-arrhythmic properties of fibrosis in ESUS and AFib are indistinguishable suggesting that some ESUS patients have a pre-clinical fibrotic substrate but do not have AFib due to a lack of suitable triggers.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
n/a this study is not a clinical trial
Funding Statement
SFB is supported by a fellowship from the ARCS foundation. CHR is supported by a Medical Research Council Skills Development Fellowship (MR/S015086/1). SAN is supported by NIH R01-HL152256, ERC PREDICT-HF (864055), BHF (RG/20/4/34803), EPSRC (EP/P01268X/1), and the Wellcome Trust (203148/Z/16/Z). DT and WTL are co-PIs for the ARCADIA trial (NIH 5-U01-NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance and ancillary funding from Roche Diagnostics. NA is supported by John Locke Charitable Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients were recruited to undergo cardiac LGE-MRI from the University of Washington (Seattle, WA) and Klinikum Coburg (Coburg, Germany) between July 2016 and June 2019. It was approved by the Institutional Review Board (IRB) of the University of Washington (UW) and the Ethikkommission der Bayerischen Ländesärztekammer München, Bayern, Deutschland; all participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Following publication, relevant data will be made available by the authors in response to reasonable requests for non-commercial reuse upon approval from the relevant Independent Ethics Committee(s).
